JP2021530237A - Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体 - Google Patents

Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体 Download PDF

Info

Publication number
JP2021530237A
JP2021530237A JP2021503011A JP2021503011A JP2021530237A JP 2021530237 A JP2021530237 A JP 2021530237A JP 2021503011 A JP2021503011 A JP 2021503011A JP 2021503011 A JP2021503011 A JP 2021503011A JP 2021530237 A JP2021530237 A JP 2021530237A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
campylobacter
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021503011A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020018584A5 (https=
JP2021530237A5 (https=
Inventor
ファビオ グラッシ，
リーサ ペッルーツァ，
マッテオ ピッツート，
ファビオ ベニーニ，
ダヴィデ コルティ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of JP2021530237A publication Critical patent/JP2021530237A/ja
Publication of JPWO2020018584A5 publication Critical patent/JPWO2020018584A5/ja
Publication of JP2021530237A5 publication Critical patent/JP2021530237A5/ja
Priority to JP2024092422A priority Critical patent/JP2024116266A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021503011A 2018-07-17 2019-07-16 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体 Ceased JP2021530237A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024092422A JP2024116266A (ja) 2018-07-17 2024-06-06 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862699573P 2018-07-17 2018-07-17
US62/699,573 2018-07-17
PCT/US2019/042070 WO2020018584A2 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024092422A Division JP2024116266A (ja) 2018-07-17 2024-06-06 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体

Publications (3)

Publication Number Publication Date
JP2021530237A true JP2021530237A (ja) 2021-11-11
JPWO2020018584A5 JPWO2020018584A5 (https=) 2022-07-11
JP2021530237A5 JP2021530237A5 (https=) 2022-07-11

Family

ID=67480448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503011A Ceased JP2021530237A (ja) 2018-07-17 2019-07-16 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体
JP2024092422A Pending JP2024116266A (ja) 2018-07-17 2024-06-06 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024092422A Pending JP2024116266A (ja) 2018-07-17 2024-06-06 Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体

Country Status (13)

Country Link
US (1) US12297258B2 (https=)
EP (1) EP3823727A2 (https=)
JP (2) JP2021530237A (https=)
KR (1) KR20210041557A (https=)
CN (1) CN112867541B (https=)
AU (1) AU2019306543A1 (https=)
BR (1) BR112021000772A2 (https=)
CA (1) CA3105222A1 (https=)
EA (1) EA202190194A1 (https=)
IL (1) IL280234A (https=)
MX (1) MX2021000268A (https=)
SG (1) SG11202013193XA (https=)
WO (1) WO2020018584A2 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142084A1 (ja) * 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2015535224A (ja) * 2012-10-24 2015-12-10 ナショナル リサーチ カウンシル オブ カナダ 抗カンピロバクター・ジェジュニ（ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ）抗体及びその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
EP1676862B1 (en) 2003-09-24 2010-12-22 Kyowa Hakko Kirin Co., Ltd. Recombinant antibody against human insulin-like growth factor
JP2008501625A (ja) * 2003-11-21 2008-01-24 エース バイオサイエンシズ エー／エス 表在Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉポリペプチド
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015535224A (ja) * 2012-10-24 2015-12-10 ナショナル リサーチ カウンシル オブ カナダ 抗カンピロバクター・ジェジュニ（ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ）抗体及びその使用
WO2014142084A1 (ja) * 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHINTOAN-UTA, C. ET AL.: ""Evaluation of flagellum-related proteins FliD and FspA as subunit vaccines against Campylobacter j", VACCINE, vol. 34, no. 15, JPN6023022260, April 2016 (2016-04-01), pages 1739 - 1743, ISSN: 0005477961 *
GIUNTINI, SERENA ET AL.: ""Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against E", INFECTION AND IMMUNITY, vol. 86, no. 8, JPN6023022261, August 2018 (2018-08-01), ISSN: 0005477962 *
YEH, HUNG-YUEH ET AL.: ""Characterization and antigenicity of recombinant Campylobacter jejuni flagellar capping protein Fl", JOURNAL OF MEDICAL MICROBIOLOGY, vol. 63, no. 4, JPN6023022259, 1 April 2014 (2014-04-01), pages 602 - 609, ISSN: 0005477960 *

Also Published As

Publication number Publication date
JP2024116266A (ja) 2024-08-27
CN112867541B (zh) 2024-08-30
CA3105222A1 (en) 2020-01-23
WO2020018584A3 (en) 2020-04-02
IL280234A (en) 2021-03-25
KR20210041557A (ko) 2021-04-15
US20210284718A1 (en) 2021-09-16
SG11202013193XA (en) 2021-02-25
AU2019306543A1 (en) 2021-01-28
EP3823727A2 (en) 2021-05-26
WO2020018584A2 (en) 2020-01-23
CN112867541A (zh) 2021-05-28
BR112021000772A2 (pt) 2021-04-13
US12297258B2 (en) 2025-05-13
MX2021000268A (es) 2021-06-08
EA202190194A1 (ru) 2021-04-16

Similar Documents

Publication Publication Date Title
US11479599B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
JP7282401B2 (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
US12415853B2 (en) Antibody against claudin 18A2 and use thereof
WO2022022445A1 (zh) 一种特异性结合冠状病毒的抗体或其抗原结合片段
EP4282880A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
CA3166627A1 (en) Antibodies against sars-cov-2 and methods of using the same
CN116023478A (zh) 冠状病毒的中和抗体或其抗原结合片段
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
CA3194162A1 (en) Antibodies against sars-cov-2
CN117460833A (zh) 表达抗ror1/抗cd3双特异性抗体的溶瘤病毒
US12297258B2 (en) Antibodies against Campylobacter species
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
HK40053364A (en) Antibodies against campylobacter species
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
WO2024086566A2 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
WO2024103251A1 (zh) 抗afp/hla02 tcr样抗体及其用途
TW202411246A (zh) 經工程化之b型肝炎病毒中和抗體及其用途
HK40102827A (zh) Dna编码的用於抵抗sars-cov-2的抗体
CN116744966A (zh) Dna编码的用于抵抗sars-cov-2的抗体
TW202210505A (zh) 抗sars-cov-2之抗體
CN116419972A (zh) 抗SARS-CoV-2抗体及其应用
EA049727B1 (ru) Антитела против muc1-c/внеклеточного домена muc1-c (muc1-c/ecd)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250723

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251120